Efrotomycin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Efrotomycin
Accession Number
DB11401
Type
Small Molecule
Groups
Vet approved
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Categories
UNII
5BPJ82Q45X
CAS number
Not Available
Weight
Average: 1145.347
Monoisotopic: 1144.593043242
Chemical Formula
C59H88N2O20
InChI Key
ZLECMEJICSWJLT-LIWMBINXSA-N
InChI
InChI=1S/C59H88N2O20/c1-15-17-19-27-39-58(8,9)53(80-56-45(67)50(74-13)49(35(7)76-56)79-57-51(75-14)44(66)48(73-12)34(6)77-57)52(68)59(71,81-39)36(16-2)54(69)60-29-23-22-25-32(4)46(72-11)33(5)47-43(65)42(64)38(78-47)26-21-18-20-24-31(3)41(63)40-37(62)28-30-61(10)55(40)70/h15,17-28,30,33-36,38-39,42-53,56-57,63-68,71H,16,29H2,1-14H3,(H,60,69)/b17-15+,20-18+,23-22+,26-21+,27-19+,31-24+,32-25+,41-40+
IUPAC Name
2-[2,3-dihydroxy-4-({3-hydroxy-5-[(4-hydroxy-3,5-dimethoxy-6-methyloxan-2-yl)oxy]-4-methoxy-6-methyloxan-2-yl}oxy)-5,5-dimethyl-6-[(1E,3E)-penta-1,3-dien-1-yl]oxan-2-yl]-N-[(2E,4E)-7-{3,4-dihydroxy-5-[(1E,3E,5E)-7-hydroxy-6-methyl-7-[(3Z)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydropyridin-3-ylidene]hepta-1,3,5-trien-1-yl]oxolan-2-yl}-6-methoxy-5-methylocta-2,4-dien-1-yl]butanimidic acid
SMILES
[H]\C(C)=C(\[H])/C(/[H])=C(\[H])C1OC(O)(C(CC)C(O)=NC\C([H])=C(/[H])\C(\[H])=C(/C)C(OC)C(C)C2OC(\C([H])=C(/[H])\C(\[H])=C(/[H])C([H])=C(C)C(\O)=C3\C(=O)C=CN(C)C3=O)C(O)C2O)C(O)C(OC2OC(C)C(OC3OC(C)C(OC)C(O)C3OC)C(OC)C2O)C1(C)C

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe risk or severity of bleeding can be increased when Efrotomycin is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding can be increased when Efrotomycin is combined with (S)-Warfarin.
4-hydroxycoumarinThe risk or severity of bleeding can be increased when Efrotomycin is combined with 4-hydroxycoumarin.
AcenocoumarolThe risk or severity of bleeding can be increased when Efrotomycin is combined with Acenocoumarol.
Adenovirus type 7 vaccine liveThe therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Efrotomycin.
Anthrax immune globulin humanThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Efrotomycin.
Anthrax vaccineThe therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Efrotomycin.
Bacillus calmette-guerin substrain connaught live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Efrotomycin.
Bacillus calmette-guerin substrain danish 1331 live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Efrotomycin.
Bacillus calmette-guerin substrain tice live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Efrotomycin.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Frost BM, Valiant ME, Weissberger B, Dulaney EL: Antibacterial activity of efrotomycin. J Antibiot (Tokyo). 1976 Oct;29(10):1083-91. [PubMed:994327]
  2. Frost BM, Valiant ME, Dulaney EL: Synergism between efrotomycin and bottromycin. J Antibiot (Tokyo). 1979 Oct;32(10):1046-9. [PubMed:528364]
  3. Wax R, Maises W, Weston R, Birnbaum J: Efrotomycin, a new antibiotic from Streptomyces lactamdurans. J Antibiot (Tokyo). 1976 Jun;29(6):670-3. [PubMed:950325]
  4. Nielsen JB, Kaplan L: A resting cell system for efrotomycin biosynthesis. J Antibiot (Tokyo). 1989 Jun;42(6):944-51. [PubMed:2737954]
  5. Stong JD: Determination of efrotomycin in feeds by high-performance liquid chromatography. Analyst. 1986 Jul;111(7):853-5. [PubMed:3752528]
  6. Chartrain M, Hunt G, Horn L, Kirpekar A, Mathre D, Powell A, Wassel L, Nielsen J, Buckland B, Greasham R: Biochemical and physiological characterization of the efrotomycin fermentation. J Ind Microbiol. 1991 Jun;7(4):293-9. [PubMed:1367328]
  7. Cover WH, Kirpekar AC, George H, Stieber RW: Calcium inhibition of efrotomycin production by Nocardia lactamdurans. J Ind Microbiol. 1991 Jan;7(1):41-4. [PubMed:1367205]
  8. Darland G, Arison B, Kaplan L: The biosynthetic origin of the pyridone ring of efrotomycin. J Ind Microbiol. 1991 Nov;8(4):265-71. [PubMed:1367801]
  9. Stutz MW, Johnson SL, Judith FR, Miller BM: In vitro and in vivo evaluations of the antibiotic efrotomycin. Poult Sci. 1983 Aug;62(8):1612-8. [PubMed:6314312]
  10. Dewey RS, Arison BH, Hannah J, Shih DH, Albers-Schonberg G: The structure of efrotomycin. J Antibiot (Tokyo). 1985 Dec;38(12):1691-8. [PubMed:4093333]
External Links
Not Available

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0166 mg/mLALOGPS
logP5.03ALOGPS
logP4.23ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)4.97ChemAxon
pKa (Strongest Basic)2.96ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count21ChemAxon
Hydrogen Donor Count8ChemAxon
Polar Surface Area303.88 Å2ChemAxon
Rotatable Bond Count23ChemAxon
Refractivity304.22 m3·mol-1ChemAxon
Polarizability124.59 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as o-glycosyl compounds. These are glycoside in which a sugar group is bonded through one carbon to another group via a O-glycosidic bond.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
O-glycosyl compounds
Alternative Parents
C-glycosyl compounds / Disaccharides / Tetrahydropyridines / Oxanes / Vinylogous amides / Vinylogous acids / Tertiary carboxylic acid amides / Oxolanes / Secondary alcohols / Cyclic ketones
show 14 more
Substituents
C-glycosyl compound / Disaccharide / O-glycosyl compound / Tetrahydropyridine / Hydropyridine / Oxane / Vinylogous amide / Vinylogous acid / Tertiary carboxylic acid amide / Oxolane
show 27 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on February 25, 2016 11:25 / Updated on June 04, 2019 07:20